Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 84272
1. Yu H, Chen T, Zhou L, Tang J: Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats. Med Sci Monit; 2017 Feb 15;23:818-825
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats.
  • However, whether 5-HT6R is involved in the development of vascular dementia (VD) remains unclear.
  • [MeSH-major] Dementia, Vascular / drug therapy. Receptors, Serotonin / metabolism. Serotonin Receptor Agonists / pharmacology
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Brain / physiopathology. Disease Models, Animal. Hippocampus / metabolism. Learning. Male. Maze Learning / drug effects. Memory / drug effects. Memory / physiology. Neurotransmitter Agents / agonists. Neurotransmitter Agents / metabolism. Random Allocation. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Neurol Neurosci. 2015;37:78-92 [26587900.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2011 May;26(3):169-83 [21429956.001]
  • [Cites] Curr Neuropharmacol. 2015;13(6):793-801 [26630957.001]
  • [Cites] Clin Interv Aging. 2015 Oct 23;10:1695-704 [26604717.001]
  • [Cites] Neural Regen Res. 2015 Sep;10(9):1418-20 [26604901.001]
  • [Cites] Expert Rev Neurother. 2014 Sep;14(9):1067-77 [25105544.001]
  • [Cites] Biol Pharm Bull. 1997 Apr;20(4):349-53 [9145208.001]
  • [Cites] Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):79-82 [25202788.001]
  • [Cites] Neurotherapeutics. 2011 Jul;8(3):361-73 [21556678.001]
  • [Cites] Evid Based Complement Alternat Med. 2014;2014:294103 [25024727.001]
  • [Cites] Curr Neurovasc Res. 2014 May;11(2):94-106 [24597602.001]
  • [Cites] J Neurol Sci. 2014 Dec 15;347(1-2):66-77 [25266713.001]
  • [Cites] Neurosci Lett. 2015 Feb 5;587:113-9 [25534501.001]
  • [Cites] Neurol Sci. 2012 Feb;33(1):39-43 [21647626.001]
  • [Cites] Cochrane Database Syst Rev. 2015 Mar 03;(3):CD009444 [25734590.001]
  • [Cites] Neuropathology. 2016 Apr;36(2):115-24 [26607405.001]
  • [Cites] Cell Physiol Biochem. 2013;31(6):761-77 [23735822.001]
  • [Cites] Lancet. 2015 Oct 24;386(10004):1698-706 [26595643.001]
  • [Cites] Curr Pharm Des. 2014;20(2):161-71 [23701539.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2013 Aug;22(6):841-5 [22784820.001]
  • [Cites] Wiad Lek. 2014;67(2 Pt 2):161-5 [25796815.001]
  • [Cites] Pharmacol Biochem Behav. 2016 Jan;140:1-7 [26549214.001]
  • (PMID = 28196966.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurotransmitter Agents; 0 / Receptors, Serotonin; 0 / Serotonin Receptor Agonists; 0 / serotonin 6 receptor
  •  go-up   go-down


2. Axmon A, Kristensson J, Ahlström G, Midlöv P: Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia. Res Dev Disabil; 2017 Mar;62:50-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia.
  • BACKGROUND: Although people with intellectual disability (ID) and people with dementia have high drug prescription rates, there is a lack of studies investigating drug use among those with concurrent diagnoses of ID and dementia.
  • AIM: To investigate the use of antipsychotics, benzodiazepine derivatives, and drugs recommended for dementia treatment (anticholinesterases [AChEIs] and memantine) among people with ID and dementia.
  • METHODS AND PROCEDURES: Having received support available for people with ID and/or autism spectrum disorder (ASD) was used as a proxy for ID.
  • People with a specialists' diagnosis of dementia during 2002-2012 were identified (ID, n=180; gPop, n=67), and data on prescription of the investigated drugs during the period 2006-2012 were collected.
  • OUTCOME AND RESULTS: People with ID/ASD and dementia were more likely than people with ID/ASD but without dementia to be prescribed antipsychotics (50% vs 39% over the study period; odds ratio (OR) 1.85, 95% confidence interval 1.13-30.3) and benzodiazepine derivatives (55% vs 36%; OR 2.42, 1.48-3.98).
  • They were also more likely than people with dementia from the general population to be prescribed antipsychotics (50% vs 25%; OR 3.18, 1.59-6.34), but less likely to be prescribed AChEIs (28% vs 45%; OR 0.32, 0.16-0.64).
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Autism Spectrum Disorder / drug therapy. Benzodiazepines / therapeutic use. Dementia / drug therapy. Intellectual Disability / drug therapy. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
  • (PMID = 28110116.001).
  • [ISSN] 1873-3379
  • [Journal-full-title] Research in developmental disabilities
  • [ISO-abbreviation] Res Dev Disabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Cholinesterase Inhibitors; 0 / Dopamine Agents; 12794-10-4 / Benzodiazepines; W8O17SJF3T / Memantine
  • [Keywords] NOTNLM ; Anticholinesterases / Drug prescription / Drug use / Memantine / Registry study / Sweden
  •  go-up   go-down


3. Sommerlad A, Singleton D, Jones R, Banerjee S, Livingston G: Development of an instrument to assess social functioning in dementia: The Social Functioning in Dementia scale (SF-DEM). Alzheimers Dement (Amst); 2017;7:88-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of an instrument to assess social functioning in dementia: The Social Functioning in Dementia scale (SF-DEM).
  • INTRODUCTION: Social functioning is a core domain in the life of people with dementia, but there is no accepted instrument to measure it.
  • We aimed to develop the Social Functioning in Dementia (SF-DEM) scale and test its psychometric properties for assessing social function in people with dementia.
  • METHODS: We interviewed people with mild dementia and family caregivers to develop patient and caregiver-rated SF-DEM versions and refined them through interviews with health care professionals.
  • We tested its psychometric properties in 30 dyads of people with dementia and family caregivers.
  • RESULTS: Both SF-DEM versions had content validity and demonstrated concurrent validity against a single item rating overall social functioning (patient rated <i>r</i> = 0.42, 95% CI [0.07-0.68]; caregiver rated <i>r</i> = 0.59, 95% CI [0.29-0.78]).
  • DISCUSSION: SF-DEM shows promise as a valid, reliable, acceptable measure of social functioning in dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Age Ageing. 1996 Mar;25(2):113-20 [8670538.001]
  • [Cites] Aging Ment Health. 2011 Nov;15(8):961-9 [21722021.001]
  • [Cites] Psychol Aging. 2009 Mar;24(1):239-44 [19290759.001]
  • [Cites] Int Psychogeriatr. 2007 Dec;19(6):1021-39 [17727738.001]
  • [Cites] Soc Sci Med. 1999 Apr;48(8):977-88 [10390038.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2015 Jun;28(2):126-35 [25431449.001]
  • [Cites] Psychol Aging. 2011 Mar;26(1):133-6 [21280951.001]
  • [Cites] Am J Public Health. 2008 Jul;98(7):1221-7 [18511731.001]
  • [Cites] Aging Ment Health. 2008 Jul;12(4):499-503 [18791898.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):438-48 [24133285.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):25-30 [17334269.001]
  • [Cites] J Clin Epidemiol. 2007 Jan;60(1):34-42 [17161752.001]
  • [Cites] Psychosom Med. 2002 May-Jun;64(3):510-9 [12021425.001]
  • [Cites] J Adv Nurs. 2006 Jun;54(6):722-38 [16796664.001]
  • [Cites] Qual Life Res. 2002 May;11(3):193-205 [12074258.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):140-5 [19204020.001]
  • [Cites] Dementia (London). 2014 May;13(3):330-49 [24339060.001]
  • [Cites] Aging Ment Health. 2009 May;13(3):426-36 [19484607.001]
  • [Cites] Health Technol Assess. 2005 Mar;9(10 ):1-93, iii-iv [15774233.001]
  • [Cites] J Clin Exp Neuropsychol. 2012;34(8):806-13 [22624797.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Health Qual Life Outcomes. 2005 Apr 05;3:23 [15811176.001]
  • [Cites] Br J Psychiatry. 1990 Dec;157:853-9 [2289094.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 1997 Jul;10(3):197-202 [9297713.001]
  • [Cites] Alzheimers Dement. 2016 Feb;12 (2):195-202 [26096665.001]
  • [Cites] Lancet Neurol. 2006 May;5(5):406-12 [16632311.001]
  • [Cites] Brain. 2013 Jun;136(Pt 6):1929-41 [23576128.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2003 Oct-Dec;17(4):201-8 [14657783.001]
  • [Cites] Int J Geriatr Psychiatry. 2004 Mar;19(3):256-65 [15027041.001]
  • [Cites] Psychol Bull. 1968 Oct;70(4):213-20 [19673146.001]
  • [Cites] Int Psychogeriatr. 2013 Jul;25(7):1135-43 [23574921.001]
  • [Cites] Clin Rehabil. 1998 Jun;12 (3):187-99 [9688034.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Jan;24(1):15-24 [18727132.001]
  • (PMID = 28317009.001).
  • [ISSN] 2352-8729
  • [Journal-full-title] Alzheimer's & dementia (Amsterdam, Netherlands)
  • [ISO-abbreviation] Alzheimers Dement (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Assessment tool / Dementia / Outcome assessment / Social functioning
  •  go-up   go-down


Advertisement
4. Kirkham J, Sherman C, Velkers C, Maxwell C, Gill S, Rochon P, Seitz D: Antipsychotic Use in Dementia. Can J Psychiatry; 2017 Mar;62(3):170-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic Use in Dementia.
  • Current controversy exists over the role of antipsychotics in the management of neuropsychiatric symptoms (NPS) in persons with dementia.
  • Approximately one-third of all persons with dementia are currently prescribed antipsychotic medications, and there is significant variation in the use of antipsychotics across care settings and providers.
  • Reducing the inappropriate or unnecessary use of antipsychotics among persons with dementia has been the focus of increasing attention owing to better awareness of the potential problems associated with these medications.
  • Several approaches can be used to curb the use of antipsychotics among persons with dementia, including policy or regulatory changes, public reporting, and educational outreach.
  • Although reducing the inappropriate use of antipsychotics is a complex task, psychiatrists can play an important role via the provision of clinical care and research evidence, contributing to improved care of persons with dementia in Canada and elsewhere.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Psychogeriatr. 2009 Jun;21(3):485-93 [19368752.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):977-85 [9256852.001]
  • [Cites] Am J Psychiatry. 2011 Aug;168(8):831-9 [21572163.001]
  • [Cites] J Am Med Dir Assoc. 2014 Oct;15(10):706-18 [25112229.001]
  • [Cites] Int J Geriatr Psychiatry. 2010 Sep;25(9):917-22 [20803721.001]
  • [Cites] J Aging Health. 1991 Nov;3(4):455-72 [10115034.001]
  • [Cites] Arch Intern Med. 2007 Apr 9;167(7):676-83 [17420426.001]
  • [Cites] Am J Geriatr Psychiatry. 2015 Dec;23(12):1259-69 [26525997.001]
  • [Cites] Am J Psychiatry. 2016 May 1;173(5):543-6 [27133416.001]
  • [Cites] Can Geriatr J. 2012 Dec;15(4):120-6 [23259025.001]
  • [Cites] Arch Intern Med. 2010 Jan 11;170(1):89-95 [20065204.001]
  • [Cites] Am J Geriatr Psychiatry. 2006 Mar;14 (3):191-210 [16505124.001]
  • [Cites] J Palliat Med. 2013 Jan;16(1):31-7 [23234299.001]
  • [Cites] Int J Geriatr Psychiatry. 2001 Jan;16(1):39-44 [11180484.001]
  • [Cites] Clin Drug Investig. 2010;30(1):63-70 [19995099.001]
  • [Cites] Int J Geriatr Psychiatry. 1997 May;12(5):533-6 [9193961.001]
  • [Cites] JAMA. 2005 Oct 19;294(15):1934-43 [16234500.001]
  • [Cites] Psychiatr Serv. 1997 Oct;48(10):1289-96 [9323748.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259 [22696318.001]
  • [Cites] Lancet Neurol. 2009 Feb;8(2):151-7 [19138567.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726 [23543555.001]
  • [Cites] Med Care. 2003 Jan;41(1 Suppl):I30-8 [12544814.001]
  • [Cites] Med Care. 2009 Sep;47(9):1000-8 [19648835.001]
  • [Cites] Health Serv Res. 2015 Aug;50(4):1069-87 [25600861.001]
  • [Cites] Drugs Aging. 2013 Jul;30(7):569-85 [23605786.001]
  • [Cites] Drugs Aging. 2012 Sep;29(9):759-69 [23018612.001]
  • [Cites] Psychiatr Serv. 1998 Feb;49(2):229-33 [9575011.001]
  • [Cites] Int Psychogeriatr. 2004 Dec;16(4):461-80 [15715361.001]
  • [Cites] JAMA. 1988 Nov 25;260(20):3016-20 [2903260.001]
  • [Cites] N Engl J Med. 2012 Oct 18;367(16):1497-507 [23075176.001]
  • [Cites] J Am Med Dir Assoc. 2012 Jul;13(6):503-506.e2 [22342481.001]
  • [Cites] Arch Intern Med. 2008 May 26;168(10):1090-6 [18504337.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):912-8 [18398935.001]
  • [Cites] CNS Drugs. 2005;19(2):91-103 [15697324.001]
  • [Cites] Am J Psychiatry. 1992 Oct;149(10):1390-2 [1530076.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Jul;22(7):632-8 [17136713.001]
  • [Cites] Int Psychogeriatr. 2011 Dec;23(10):1632-9 [21813036.001]
  • [Cites] J Am Med Dir Assoc. 2011 Nov;12(9):648-54 [21450189.001]
  • [Cites] Int J Geriatr Psychiatry. 2002 May;17(5):403-8 [11994927.001]
  • [Cites] Eur Neuropsychopharmacol. 2013 Sep;23(9):1034-42 [23498307.001]
  • [Cites] Eur Neuropsychopharmacol. 2014 Jan;24(1):95-104 [24126116.001]
  • [Cites] Int Psychogeriatr. 2004 Mar;16(1):61-74 [15190997.001]
  • [Cites] Am J Psychiatry. 2016 Mar 1;173(3):252-62 [26585409.001]
  • [Cites] Am J Geriatr Psychiatry. 2007 May;15(5):416-24 [17463191.001]
  • [Cites] Ann Intern Med. 2008 Jan 15;148(2):111-23 [18195336.001]
  • [Cites] Int Psychogeriatr. 2010 Feb;22(1):120-8 [19735591.001]
  • [Cites] J Am Geriatr Soc. 2006 Jan;54(1):104-9 [16420205.001]
  • [Cites] CMAJ. 2008 Aug 26;179(5):438-46 [18725616.001]
  • [Cites] J Am Geriatr Soc. 2016 Feb;64(2):299-305 [26889839.001]
  • [Cites] Int Psychogeriatr. 2006 Dec;18(4):713-26 [16879762.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):358-62 [8283585.001]
  • [Cites] JAMA. 2002 Sep 25;288(12):1475-83 [12243634.001]
  • [Cites] Alzheimers Dement. 2012 Sep;8(5):453-7 [22285636.001]
  • [Cites] Br J Psychiatry. 2012 Sep;201(3):221-6 [22790679.001]
  • [Cites] Nurs Res. 2006 Jul-Aug;55(4):252-8 [16849977.001]
  • [Cites] Arch Gen Psychiatry. 2011 Feb;68(2):190-7 [21300946.001]
  • [Cites] Drugs Aging. 2005;22(9):793-800 [16156683.001]
  • [Cites] J Am Geriatr Soc. 2009 Dec;57(12):2269-74 [19874411.001]
  • [Cites] J Health Polit Policy Law. 2006 Aug;31(4):773-810 [16971545.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2007 Jun;20(2):100-6 [17548780.001]
  • [Cites] Hum Psychopharmacol. 2011 Jan;26(1):12-20 [21394786.001]
  • [Cites] BMJ. 2011 Jun 21;342:d3514 [21693525.001]
  • [Cites] Int Psychogeriatr. 2001 Mar;13(1):93-106 [11352339.001]
  • [Cites] JAMA. 2013 Feb 6;309(5):440-2 [23385262.001]
  • [Cites] J Am Geriatr Soc. 2011 Nov;59(11):2100-7 [22092099.001]
  • [Cites] Int Psychogeriatr. 2011 Oct;23(8):1240-8 [21418723.001]
  • [Cites] Am J Public Health. 1995 Jun;85(6):771-6 [7762708.001]
  • [Cites] Int Clin Psychopharmacol. 2009 Mar;24(2):97-104 [21456106.001]
  • [Cites] Health Aff (Millwood). 2009 Sep-Oct;28(5):w770-81 [19622537.001]
  • [Cites] Int J Psychiatry Med. 2010;40(4):425-38 [21391413.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Sep;22(9):843-9 [17193341.001]
  • [Cites] J Am Geriatr Soc. 2014 Mar;62(3):454-61 [24617991.001]
  • [Cites] Age Ageing. 2006 Sep;35(5):508-13 [16807310.001]
  • [Cites] Am J Psychiatry. 2008 Jul;165(7):844-54 [18519523.001]
  • [Cites] Drugs Aging. 2009;26(6):483-92 [19591523.001]
  • [Cites] Am J Public Health. 1980 May;70(5):485-91 [6103676.001]
  • [Cites] Int J Geriatr Psychiatry. 2010 Feb;25(2):160-5 [19513989.001]
  • [Cites] Int Psychogeriatr. 2012 Jun;24(6):940-7 [22333005.001]
  • [Cites] Age Ageing. 2011 May;40(3):368-75 [21429950.001]
  • [Cites] Pharmacotherapy. 1995 Jul-Aug;15(4):495-501 [7479203.001]
  • [Cites] Dtsch Arztebl Int. 2010 May;107(18):320-7 [20517530.001]
  • [Cites] Psychiatr Serv. 1996 Sep;47(9):951-5 [8875659.001]
  • [Cites] Int J Geriatr Psychiatry. 2003 Dec;18(12):1135-41 [14677146.001]
  • [Cites] BMJ. 2015 Mar 02;350:h369 [25731881.001]
  • [Cites] Med Care. 2014 Mar;52(3):267-71 [24374410.001]
  • [Cites] Int Psychogeriatr. 2013 Sep;25(9):1415-23 [23782794.001]
  • [Cites] Prim Care Companion J Clin Psychiatry. 2008;10(2):97-102 [18458729.001]
  • [Cites] Drugs Aging. 2005;22(4):339-51 [15839722.001]
  • [Cites] Int Psychogeriatr. 2014 Mar;26(3):363-71 [24252349.001]
  • [Cites] BMJ Open. 2013 Jan 07;3(1):null [23299113.001]
  • [Cites] JAMA. 2000 Apr 12;283(14 ):1866-74 [10770149.001]
  • (PMID = 28212496.001).
  • [ISSN] 1497-0015
  • [Journal-full-title] Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • [ISO-abbreviation] Can J Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; adverse events / antipsychotics / dementia / long-term care / quality improvement / quality of care
  •  go-up   go-down


5. Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, He B, Xu Y, Zou J, Yang X, Weng R, Tan S, McElroy C, Jin K, Wang Q: Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci; 2017;9:26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study.
  • <b>Objectives</b>: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD).
  • However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown.
  • <b>Methods</b>: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls.
  • The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski).
  • Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects.
  • <b>Conclusions</b>: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Aging Neurosci. 2015 Oct 27;7:203 [26578949.001]
  • [Cites] Curr Alzheimer Res. 2011 Mar;8(2):187-96 [21222606.001]
  • [Cites] J Alzheimers Dis. 2014;40(2):399-408 [24448787.001]
  • [Cites] Curr Alzheimer Res. 2014 May;11(4):340-8 [24720893.001]
  • [Cites] PLoS One. 2013;8(1):e55328 [23383156.001]
  • [Cites] Prog Neurobiol. 2013 Nov;110:2-28 [24036231.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1072-9 [18824671.001]
  • [Cites] Front Aging Neurosci. 2014 Jun 12;6:121 [24971061.001]
  • [Cites] Neurology. 1993 Feb;43(2):250-60 [8094895.001]
  • [Cites] Front Cell Neurosci. 2012 Dec 12;6:58 [23248582.001]
  • [Cites] Brain. 2011 Jan;134(Pt 1):258-77 [21186265.001]
  • [Cites] Front Cell Neurosci. 2014 Aug 14;8:231 [25177270.001]
  • [Cites] J Alzheimers Dis. 2010;21(2):471-8 [20555147.001]
  • [Cites] Cell Metab. 2014 Apr 1;19(4):574-91 [24508505.001]
  • [Cites] Neurology. 2014 Jul 1;83(1):40-7 [24907234.001]
  • [Cites] Front Mol Neurosci. 2012 Jul 06;5:79 [22783166.001]
  • [Cites] Front Aging Neurosci. 2016 Jul 28;8:179 [27516739.001]
  • [Cites] Neurobiol Aging. 2013 May;34(5):1389-96 [23273574.001]
  • [Cites] Front Aging Neurosci. 2010 Jul 15;2:null [20725527.001]
  • [Cites] J Alzheimers Dis. 2010;22(3):985-91 [20858959.001]
  • [Cites] J Neurochem. 2012 Aug;122(4):752-63 [22679891.001]
  • [Cites] Neurobiol Dis. 2014 Dec;72 Pt A:22-36 [25131449.001]
  • [Cites] Aging Dis. 2013 Mar 07;4(2):57-64 [23696950.001]
  • [Cites] Mol Neurodegener. 2015 Dec 01;10:64 [26627638.001]
  • [Cites] Mol Neurobiol. 2014 Apr;49(2):1043-54 [24203677.001]
  • [Cites] J Alzheimers Dis. 2009;16(2):389-97 [19221428.001]
  • [Cites] Front Cell Neurosci. 2015 Jul 06;9:247 [26217177.001]
  • [Cites] Front Biosci (Schol Ed). 2011 Jan 01;3:541-54 [21196395.001]
  • [Cites] Aging Dis. 2015 Oct 01;6(5):322-30 [26425387.001]
  • [Cites] PLoS One. 2013 Apr 23;8(4):e62354 [23626805.001]
  • [Cites] Neurology. 2014 Nov 11;83(20):1812-8 [25305153.001]
  • [Cites] Autophagy. 2011 Jul;7(7):788-9 [21464620.001]
  • [Cites] Sci Rep. 2016 Aug 04;6:30741 [27489174.001]
  • [Cites] Neurobiol Dis. 2005 Feb;18(1):152-65 [15649706.001]
  • [Cites] Am J Pathol. 2010 Nov;177(5):2256-67 [20889561.001]
  • [Cites] Front Aging Neurosci. 2013 Sep 09;5:50 [24058343.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1440-2 [18026100.001]
  • [Cites] Neurobiol Aging. 2011 Aug;32(8):1435-42 [19773092.001]
  • [Cites] Brain. 2014 Dec;137(Pt 12):3300-18 [25270989.001]
  • [Cites] Prog Neurobiol. 2015 Jul 21;:null [26209472.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28223934.001).
  • [ISSN] 1663-4365
  • [Journal-full-title] Frontiers in aging neuroscience
  • [ISO-abbreviation] Front Aging Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Alzheimer’s disease / cystatin C / dementia / high-density lipoprotein / vascular dementia
  •  go-up   go-down


6. Yang YW, Liu HH, Lin TH, Chuang HY, Hsieh T: Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS One; 2017;12(4):e0175335
MedlinePlus Health Information. consumer health - Diabetes Complications.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.
  • BACKGROUND: The effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with diabetes mellitus (DM) remain unknown.
  • We investigated the effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with DM.
  • We included 10,938 patients received one type of oxybutynin, solifenacin, or tolterodine, while 564,733 had not.
  • The dementia risk was estimated through multivariate Cox proportional hazard regression after adjustment for several confounding factors.
  • RESULTS: The dementia event rates were 3.9% in the oxybutynin group, 4.3% in the solifenacin group, 2.2% in the tolterodine group and 1.2% in the control group (P<0.001).
  • CONCLUSION: Our study indicates an association between taking oxybutynin, solifenacin and tolterodine and the subsequent diagnosis of dementia in DM patients.
  • The impact of these three drugs on risk of dementia in non-diabetic populations is warrant.
  • [MeSH-major] Cholinergic Antagonists / therapeutic use. Dementia / chemically induced. Diabetes Complications

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Dementia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urogynecol J. 2011 Aug;22(8):907-17 [21468739.001]
  • [Cites] Int J Clin Pract. 2010 Aug;64(9):1279-86 [20529135.001]
  • [Cites] Pharmacology. 2009;83(5):259-69 [19295256.001]
  • [Cites] Stroke. 2008 Oct;39(10):2744-8 [18583554.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1388-95 [18454794.001]
  • [Cites] J Urol. 2015 May;193(5):1572-80 [25623739.001]
  • [Cites] Pharmacol Ther. 2008 Feb;117(2):232-43 [18082893.001]
  • [Cites] Eur Urol. 2011 Mar;59(3):377-86 [21168951.001]
  • [Cites] JAMA. 2015 Jul 21;314(3):265-77 [26197187.001]
  • [Cites] BMJ. 2016 Mar 30;352:i1541 [27029385.001]
  • [Cites] Health Policy Plan. 2016 Feb;31(1):83-90 [25944704.001]
  • [Cites] PLoS One. 2014 Jan 29;9(1):e87095 [24489845.001]
  • [Cites] Eur Urol. 2014 Apr;65(4):755-65 [24275310.001]
  • [Cites] Endocr J. 2015;62(9):847-54 [26166691.001]
  • [Cites] JAMA Intern Med. 2015 Sep;175(9):1527-9 [26192815.001]
  • [Cites] Med Care. 2015 Feb;53(2):106-15 [25397966.001]
  • [Cites] Urology. 2011 Nov;78(5):1040-5 [21958505.001]
  • [Cites] BMJ. 2003 Apr 19;326(7394):841-4 [12702614.001]
  • [Cites] Eur Urol. 2013 Jul;64(1):74-81 [23332882.001]
  • [Cites] Arch Neurol. 2003 May;60(5):771-3 [12756144.001]
  • [Cites] J Formos Med Assoc. 2005 Mar;104(3):157-63 [15818428.001]
  • [Cites] Age Ageing. 2014 Sep;43(5):604-15 [25038833.001]
  • [Cites] Endocrine. 2016 Aug;53(2):350-63 [27160819.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Oct 15;22(8):739-47 [16197495.001]
  • (PMID = 28384267.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Antagonists
  •  go-up   go-down


7. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, Chang YP: Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS One; 2017;12(2):e0171006
MedlinePlus Health Information. consumer health - Dementia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.
  • INTRODUCTION: Concerns have been raised regarding the potential association between proton pump inhibitor (PPI) use and dementia.
  • METHODS: Patients initiating PPI therapy between January 1, 2000 and December 31, 2003 without a prior history of dementia were identified from Taiwan's National Health Insurance Research Database.
  • The outcome of interest was all-cause dementia.
  • Cox regression models were applied to estimate the hazard ratio (HR) of dementia.
  • The cumulative PPI dosage stratified by quartiles of defined daily doses and adjusted for baseline disease risk score served as the primary variables compared against no PPI use.
  • RESULTS: We analyzed the data of 15726 participants aged 40 years or older and free of dementia at baseline.
  • PPI users (n = 7863; average follow-up 8.44 years) had a significantly increased risk of dementia over non-PPI users (n = 7863; average follow-up 9.55 years) (adjusted HR [aHR] 1.22; 95% confidence interval: 1.05-1.42).
  • A significant association was observed between cumulative PPI use and risk of dementia (P for trend = .013).
  • Subgroup analysis showed excess frequency of dementia in PPI users diagnosed with depression (aHR 2.73 [1.91-3.89]), hyperlipidemia (aHR 1.81 [1.38-2.38]), ischemic heart disease (aHR 1.55 [1.12-2.14]), and hypertension (aHR 1.54 [1.21-1.95]).
  • CONCLUSIONS: An increased risk for dementia was identified among the Asian PPI users.
  • Cumulative PPI use was significantly associated with dementia.
  • Further investigation into the possible biological mechanisms underlying the relationship between dementia and PPI use is warranted.
  • [MeSH-major] Databases, Factual. Dementia / chemically induced. Dementia / epidemiology. Proton Pump Inhibitors / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1019-24 [20623646.001]
  • [Cites] PLoS One. 2015 Jun 10;10(6):e0124653 [26061035.001]
  • [Cites] Aliment Pharmacol Ther. 2012 Nov;36(10):941-9 [23034135.001]
  • [Cites] Aust N Z J Psychiatry. 2001 Dec;35(6):776-81 [11990888.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Oct;64(10):935-51 [18679668.001]
  • [Cites] Arch Neurol. 2004 Aug;61(8):1290-3 [15313849.001]
  • [Cites] Circulation. 2013 Aug 20;128(8):845-53 [23825361.001]
  • [Cites] Br J Nutr. 2012 Dec 14;108(11):1948-61 [23084026.001]
  • [Cites] Biochim Biophys Acta. 1991 Jun 18;1065(2):261-8 [1647821.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Aliment Pharmacol Ther. 1991 Jun;5(3):245-54 [1888824.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1490-6 [17314396.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:9-22 [16700899.001]
  • [Cites] BMJ. 2012 Jan 30;344:e372 [22294756.001]
  • [Cites] J Clin Pharm Ther. 2010 Apr;35(2):125-6 [20456731.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:2-8 [16700898.001]
  • [Cites] Eur J Epidemiol. 2010 Apr;25(4):245-51 [20358262.001]
  • [Cites] Nat Rev Neurol. 2011 May 03;7(6):323-31 [21537355.001]
  • [Cites] PLoS One. 2013;8(3):e58837 [23520537.001]
  • [Cites] JAMA Neurol. 2016 Apr;73(4):410-6 [26882076.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2015 Aug;265(5):419-28 [25341874.001]
  • [Cites] Neurology. 2007 Dec 11;69(24):2197-204 [17568013.001]
  • [Cites] J Alzheimers Dis. 2010;19(2):573-89 [20110603.001]
  • [Cites] Psychosom Med. 2013 Jan;75(1):20-9 [23213264.001]
  • [Cites] BMJ. 2008 Jan 5;336(7634):2-3 [18174564.001]
  • [Cites] Alzheimers Dement. 2007 Jul;3(3):186-91 [19595937.001]
  • [Cites] Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329 [23419381.001]
  • [Cites] Medicine (Baltimore). 2016 May;95(21):e3658 [27227925.001]
  • [Cites] JAMA. 2013 Dec 11;310(22):2435-42 [24327038.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Biochem J. 2002 May 1;363(Pt 3):417-29 [11964142.001]
  • [Cites] Arch Gen Psychiatry. 2011 Sep;68(9):970-7 [21893662.001]
  • [Cites] Alzheimers Dement. 2013 Jan;9(1):1-11.e3 [23305821.001]
  • [Cites] J Alzheimers Dis. 2014;42(1):193-200 [24840566.001]
  • [Cites] JAMA Intern Med. 2016 Feb;176(2):238-46 [26752337.001]
  • [Cites] Lancet Neurol. 2006 Nov;5(11):949-60 [17052662.001]
  • [Cites] Ann Neurol. 2015 Aug;78(2):284-94 [25974006.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):1857-70 [10806097.001]
  • (PMID = 28199356.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


8. Yang JS, Wu XH, Yu HG, Teng LS: Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats. Inflammopharmacology; 2017 Aug;25(4):471-484
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.
  • Our aim was to investigate whether tangeretin, a citrus flavonoid, was able to prevent neuroinflammation and improve dementia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced rodent model of Parkinson's disease (PD).
  • The experimental data suggest tangeretin as an effective candidate drug with potential for prevention and treatment of neuroinflammation and dementia associated with PD.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Brain Res. 2011 Jun 1;219(2):280-90 [21262271.001]
  • [Cites] Neurotox Res. 2016 Feb;29(2):275-87 [26607911.001]
  • [Cites] Neurosci Lett. 2000 Jun 23;287(2):117-20 [10854726.001]
  • [Cites] Behav Brain Res. 2008 Apr 9;188(2):310-5 [18178264.001]
  • [Cites] J Neurosci Methods. 2005 Oct 15;148(1):78-87 [15939479.001]
  • [Cites] Behav Brain Res. 1988 Nov 1;31(1):47-59 [3228475.001]
  • [Cites] Eur J Neurosci. 2001 Feb;13(3):529-38 [11168560.001]
  • [Cites] J Agric Food Chem. 2008 Aug 13;56(15):6185-205 [18593176.001]
  • [Cites] Clin Neurosci Res. 2006 Dec 6;6(5):261-281 [18060039.001]
  • [Cites] Neuroscience. 2004;127(2):289-300 [15262320.001]
  • [Cites] J Neurol. 2000 Apr;247 Suppl 2:II25-35 [10991662.001]
  • [Cites] Glia. 2005 Nov 1;52(2):144-52 [15920722.001]
  • [Cites] Trends Mol Med. 2013 Mar;19(3):187-96 [23318001.001]
  • [Cites] Acta Anaesthesiol Scand. 2013 Mar;57(3):380-90 [23186353.001]
  • [Cites] Front Biosci. 2003 Sep 01;8:s992-7 [12957858.001]
  • [Cites] Behav Brain Res. 2014 Jul 15;268:177-84 [24755306.001]
  • [Cites] Eur J Neurosci. 2003 Sep;18(5):1175-88 [12956716.001]
  • [Cites] Neurobiol Aging. 2012 Aug;33(8):1777-91 [21524431.001]
  • [Cites] Neurosci Lett. 1998 Jun 26;250(1):25-8 [9696057.001]
  • [Cites] Neuropsychologia. 2003;41(5):565-74 [12559149.001]
  • [Cites] J Neurosci. 2005 Mar 2;25(9):2322-9 [15745958.001]
  • [Cites] Behav Brain Res. 2001 Sep 28;124(1):9-18 [11423161.001]
  • [Cites] FASEB J. 2003 Mar;17 (3):500-2 [12631585.001]
  • [Cites] Eur J Pharmacol. 2003 Dec 15;482(1-3):215-22 [14660025.001]
  • [Cites] Neuroscience. 1999 Jan;88(1):1-16 [10051185.001]
  • [Cites] Exp Neurol. 2005 Oct;195(2):322-9 [16005872.001]
  • [Cites] Lancet Neurol. 2003 Apr;2(4):229-37 [12849211.001]
  • [Cites] Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S3-7 [15109580.001]
  • [Cites] Mediators Inflamm. 2013;2013:952375 [23935251.001]
  • [Cites] FASEB J. 2006 Apr;20(6):670-82 [16581975.001]
  • [Cites] Restor Neurol Neurosci. 2013;31(1):87-97 [23047495.001]
  • [Cites] J Neuroimmunol. 2008 Nov 15;204(1-2):43-51 [18817984.001]
  • [Cites] Food Chem Toxicol. 2014 Sep;71:176-82 [24955543.001]
  • [Cites] Cancer Chemother Pharmacol. 2015 Feb;75(2):263-72 [25431347.001]
  • [Cites] Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2 [22166438.001]
  • [Cites] J Food Sci. 2016 May;81(5):H1320-7 [27095513.001]
  • [Cites] Neuroimage. 2006 Oct 15;33(1):374-82 [16904344.001]
  • [Cites] Behav Neurosci. 1988 Oct;102(5):748-59 [2904271.001]
  • [Cites] Acta Neuropathol. 2003 Dec;106(6):518-26 [14513261.001]
  • [Cites] Behav Brain Res. 2012 Apr 1;229(1):41-7 [22227506.001]
  • [Cites] Neurobiol Learn Mem. 2008 Feb;89(2):192-8 [17702614.001]
  • [Cites] Brain Res Bull. 2001 May 1;55(1):101-6 [11427344.001]
  • [Cites] J Neurosci. 2004 May 12;24(19):4596-604 [15140931.001]
  • [Cites] Hippocampus. 2005;15(8):1050-6 [16145694.001]
  • [Cites] J Neurosci Res. 1999 May 15;56(4):441-6 [10340751.001]
  • [Cites] Behav Brain Res. 2006 Apr 25;169(1):142-9 [16455144.001]
  • [Cites] Curr Alzheimer Res. 2005 Jul;2(3):355-65 [15974901.001]
  • [Cites] Neurobiol Learn Mem. 2008 May;89(4):522-32 [18304843.001]
  • [Cites] Neuroscience. 2005;133(3):831-40 [15893432.001]
  • [Cites] Prog Neurobiol. 2000 Sep;62(1):63-88 [10821982.001]
  • [Cites] Immunopharmacology. 1998 Jun;39(3):167-80 [9754903.001]
  • [Cites] Neuropharmacology. 2008 Mar;54(3):620-7 [18164319.001]
  • [Cites] Neuroreport. 2001 Dec 4;12(17):3871-5 [11726811.001]
  • [Cites] J Neurosci. 2000 Aug 1;20(15):5715-23 [10908611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1498-502 [3221216.001]
  • [Cites] Behav Brain Res. 2010 Mar 17;208(1):38-46 [19900486.001]
  • [Cites] Neurosci Res. 2006 Sep;56(1):96-102 [16846658.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1404-10 [15851731.001]
  • [Cites] Exp Neurol. 2005 Mar;192(1):134-41 [15698627.001]
  • [Cites] Brain Res. 2000 Mar 31;860(1-2):190-4 [10727642.001]
  • [Cites] Biomed Pharmacother. 2016 Jul;81:491-6 [27261630.001]
  • [Cites] Neuropharmacology. 2015 Apr;91:43-56 [25499022.001]
  • [Cites] Nat Neurosci. 2001 Jul;4(7):702-10 [11426226.001]
  • [Cites] J Neural Transm Suppl. 2000;(58):143-51 [11128604.001]
  • [Cites] Am J Psychiatry. 1995 Sep;152(9):1291-7 [7653683.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):598-605 [10514096.001]
  • [Cites] Dev Neurosci. 1998;20(1):1-18 [9600386.001]
  • [Cites] Neurobiol Dis. 2008 Nov;32(2):319-27 [18718537.001]
  • [Cites] Nat Rev Neurol. 2010 Apr;6(4):193-201 [20234358.001]
  • [Cites] J Am Assoc Lab Anim Sci. 2011 Jan;50(1):41-5 [21333162.001]
  • [Cites] Behav Neurosci. 2009 Dec;123(6):1261-70 [20001109.001]
  • [Cites] Pharmacol Biochem Behav. 2010 Apr;95(2):158-65 [20064549.001]
  • [Cites] Eur J Pharmacol. 2008 Oct 10;594(1-3):101-8 [18674531.001]
  • [Cites] Phytother Res. 2013 Apr;27(4):564-71 [22678994.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S9-S15 [15885630.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(8):963-76 [17339843.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):141-50 [15619128.001]
  • [Cites] Mol Genet Metab. 1998 Feb;63(2):142-7 [9562968.001]
  • [Cites] Glia. 2004 May;46(4):402-9 [15095370.001]
  • [Cites] Neurotoxicology. 2012 Mar;33(2):147-55 [22281204.001]
  • [Cites] Neurosci Lett. 2003 May 1;341(2):87-90 [12686372.001]
  • [Cites] Mov Disord. 2006 Sep;21(9):1483-7 [16705661.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jul;102(1):64-71 [22487770.001]
  • [Cites] J Neuroimmune Pharmacol. 2016 Jun;11(2):294-305 [26899309.001]
  • (PMID = 28577132.001).
  • [ISSN] 1568-5608
  • [Journal-full-title] Inflammopharmacology
  • [ISO-abbreviation] Inflammopharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) / Dementia / Inflammatory cytokines / Neurodegeneration / Parkinson’s disease / Tangeretin
  •  go-up   go-down


9. Wolters FJ, Zonneveld HI, Hofman A, van der Lugt A, Koudstaal PJ, Vernooij MW, Ikram MA, Heart-Brain Connection Collaborative Research Group: Cerebral Perfusion and the Risk of Dementia: A Population-Based Study. Circulation; 2017 Aug 22;136(8):719-728

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral Perfusion and the Risk of Dementia: A Population-Based Study.
  • BACKGROUND: Cerebral hypoperfusion has previously been associated with mild cognitive impairment and dementia in various cross-sectional studies, but whether hypoperfusion precedes neurodegeneration is unknown.
  • We prospectively determined the association of cerebral perfusion with subsequent cognitive decline and development of dementia.
  • METHODS: Between 2005 and 2012, we measured cerebral blood flow by 2-dimensional phase-contrast magnetic resonance imaging in participants of the population-based Rotterdam Study without dementia.
  • We determined the association of cerebral perfusion (mL/100mL/min) with risk of dementia (until 2015) using a Cox model, adjusting for age, sex, demographics, cardiovascular risk factors, and apolipoprotein E genotype.
  • We repeated analyses for Alzheimer disease and accounting for stroke.
  • RESULTS: Of 4759 participants (median age 61.3 years, 55.2% women) with a median follow-up of 6.9 years, 123 participants developed dementia (97 Alzheimer disease).
  • Lower cerebral perfusion was associated with higher risk of dementia (adjusted hazard ratio, 1.31; 95% confidence interval per standard deviation decrease, 1.07-1.61), similar for Alzheimer disease only, and unaltered by accounting for stroke.
  • Risk of dementia with hypoperfusion was higher with increasing severity of white matter hyperintensities (with severe white matter hyperintensities; hazard ratio, 1.54; 95% confidence interval, 1.11-2.14).
  • At cognitive reexamination after on average 5.7 years, lower baseline perfusion was associated with accelerated decline in cognition (global cognition: β=-0.029, <i>P</i>=0.003), which was similar after excluding those with incident dementia, and again most profound in individuals with higher volume of white matter hyperintensities (<i>P</i> value for interaction=0.019).
  • CONCLUSIONS: Cerebral hypoperfusion is associated with accelerated cognitive decline and an increased risk of dementia in the general population.
  • [MeSH-major] Cerebrovascular Circulation / physiology. Dementia / diagnostic imaging. Dementia / epidemiology. Population Surveillance. White Matter / blood supply. White Matter / diagnostic imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28588075.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alzheimer disease / cerebral blood flow / cerebral perfusion / dementia / epidemiology / small-vessel disease
  •  go-up   go-down


10. Pilotto A, Gazzina S, Benussi A, Manes M, Dell'Era V, Cristillo V, Cosseddu M, Turrone R, Alberici A, Padovani A, Borroni B: Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy. Neurodegener Dis; 2017 Sep 08;17(6):286-291
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy.
  • BACKGROUND: Cognitive deficits are common in progressive supranuclear palsy (PSP), but their relevance and the progression to dementia are still poorly described.
  • METHODS: The study retrospectively evaluated a series of 99 PSP patients with Richardson syndrome (PSP-RS), subgrouped according to cognitive and behavioural performances into PSP with normal cognition (PSP-NC), PSP with mild cognitive impairment (PSP-MCI), and PSP with dementia (PSP-D).
  • The progression to dementia at the 3-year follow-up was assessed.
  • During the 3-year follow-up, 21 out of 29 patients, previously classified as PSP-NC or PSP-MCI, converted to dementia, with an incidence rate of 241 per 1,000 patients/year.
  • Nineteen out of 21 PSP patients (90%) developed the behavioural variant frontotemporal dementia phenotype.
  • The only factor associated with conversion to dementia was MCI diagnosis at baseline (p = 0.023).
  • CONCLUSION: Cognitive decline occurs in a great proportion of PSP-RS patients early during the disease course.
  • In the absence of a specific phenotype, the diagnosis of MCI might identify PSP patients at greatest risk of developing dementia and should be considered further in the diagnostic assessment.

  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28881351.001).
  • [ISSN] 1660-2862
  • [Journal-full-title] Neuro-degenerative diseases
  • [ISO-abbreviation] Neurodegener Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Cognitive dysfunction / Dementia / Predictors / Progressive supranuclear palsy
  •  go-up   go-down






Advertisement